AU2002211710A1 - Cytomegalovirus intron a fragments - Google Patents

Cytomegalovirus intron a fragments

Info

Publication number
AU2002211710A1
AU2002211710A1 AU2002211710A AU1171002A AU2002211710A1 AU 2002211710 A1 AU2002211710 A1 AU 2002211710A1 AU 2002211710 A AU2002211710 A AU 2002211710A AU 1171002 A AU1171002 A AU 1171002A AU 2002211710 A1 AU2002211710 A1 AU 2002211710A1
Authority
AU
Australia
Prior art keywords
fragments
intron
cytomegalovirus
cytomegalovirus intron
cmv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002211710A
Inventor
Mark Selby
Kent Thudium
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2002211710A1 publication Critical patent/AU2002211710A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C12N2840/445—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor for trans-splicing, e.g. polypyrimidine tract, branch point splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Perforating, Stamping-Out Or Severing By Means Other Than Cutting (AREA)
  • Package Closures (AREA)
  • Separation, Recovery Or Treatment Of Waste Materials Containing Plastics (AREA)

Abstract

Cytomegalovirus (CMV) Intron A fragments for expressing gene products are disclosed. Also described are expression vectors including the fragments, as well as methods of using the same.
AU2002211710A 2000-10-13 2001-10-12 Cytomegalovirus intron a fragments Abandoned AU2002211710A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24050200P 2000-10-13 2000-10-13
US60/240,502 2000-10-13
PCT/US2001/032050 WO2002031137A2 (en) 2000-10-13 2001-10-12 Cytomegalovirus intron a fragments

Publications (1)

Publication Number Publication Date
AU2002211710A1 true AU2002211710A1 (en) 2002-04-22

Family

ID=22906778

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002211710A Abandoned AU2002211710A1 (en) 2000-10-13 2001-10-12 Cytomegalovirus intron a fragments

Country Status (11)

Country Link
US (2) US6893840B2 (en)
EP (1) EP1373524B1 (en)
JP (1) JP4445703B2 (en)
CN (1) CN1247785C (en)
AT (1) ATE323166T1 (en)
AU (1) AU2002211710A1 (en)
CA (1) CA2425852C (en)
DE (1) DE60118798T2 (en)
ES (1) ES2261489T3 (en)
WO (1) WO2002031137A2 (en)
ZA (1) ZA200302667B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0027088D0 (en) * 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
JP3630414B2 (en) 2002-05-21 2005-03-16 インターナショナル・ビジネス・マシーンズ・コーポレーション Base sequence cluster generation system, base sequence cluster generation method, program for executing the cluster generation method, computer-readable recording medium storing the program, and base sequence information providing system
ATE505538T1 (en) * 2003-06-09 2011-04-15 Corixa Corp DNA VECTORS
KR101225395B1 (en) 2003-10-10 2013-01-28 파우더젝트 백신, 인코포레이티드 Nucleic Acid Constructs
EA010059B1 (en) * 2003-10-14 2008-06-30 Байоджен Айдек Ма Инк. Flp-mediated recombination
GB0507997D0 (en) * 2005-02-01 2005-05-25 Powderject Vaccines Inc Nucleic acid constructs
WO2006111387A2 (en) * 2005-04-22 2006-10-26 Lonza Biologics Plc. Mammalian expression vector comprising the mcmv promoter and first intron of hcmv major immediate early gene
EP2446034A4 (en) * 2009-06-22 2013-11-27 Ipca Lab Ltd Novel polynucleotide molecules for enhanced gene expression
CN102695794B (en) * 2009-09-04 2014-11-05 独立行政法人医药基盘研究所 Enhancer for promoter, and use thereof
US20120100573A1 (en) * 2010-10-21 2012-04-26 Thudium Kent B Cytomegalovirus intron a fragments
CN105392885B (en) 2013-07-19 2020-11-03 赖瑞克斯生物科技公司 Methods and compositions for generating double allele knockouts
US11060083B2 (en) 2013-07-19 2021-07-13 Larix Bioscience Llc Methods and compositions for producing double allele knock outs
FI3851537T3 (en) * 2014-04-25 2024-03-21 Genethon Treatment of hyperbilirubinemia
US11617788B2 (en) 2018-07-09 2023-04-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Viral promoters and compositions and methods of use thereof
KR20210080071A (en) * 2019-12-20 2021-06-30 (주)셀트리온 Expression cassette for expressing target protein highly and method for using the same
JP2023509118A (en) 2019-12-24 2023-03-07 アスクレピオス バイオファーマシューティカル， インコーポレイテッド regulatory nucleic acid sequence
GB202005732D0 (en) 2020-04-20 2020-06-03 Synpromics Ltd Regulatory nucleic acid sequences
US20230250416A1 (en) 2020-07-06 2023-08-10 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Intron-encoded extranuclear transcripts for protein translation, rna encoding, and multi-timepoint interrogation of non-coding or protein-coding rna regulation
CN114958914B (en) * 2022-06-06 2023-09-26 新乡医学院 Human and mammal cell attachment body expression vector, construction method and application

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939018A (en) * 1984-10-10 1999-08-17 Kawasaki Steel Corporation Martensitic stainless steels for seamless steel pipe
CA1341423C (en) * 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
US5620896A (en) * 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
US5739018A (en) 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
US6025338A (en) * 1996-10-17 2000-02-15 University Of Florida Nucleic acid vaccines against rickettsial diseases and methods of use
DE60003151T2 (en) * 1999-01-13 2004-04-08 Johns Hopkins University School Of Medicine GENETIC IMMUNIZATION WITH SIMULTANEOUS ADMINISTRATION OF NUCLEIC ACIDS AND CYTOKINES
EP1200622A4 (en) * 1999-07-06 2004-12-22 Merck & Co Inc Adenovirus carrying gag gene hiv vaccine

Also Published As

Publication number Publication date
JP2004511229A (en) 2004-04-15
US6893840B2 (en) 2005-05-17
DE60118798D1 (en) 2006-05-24
ES2261489T3 (en) 2006-11-16
US20050191727A1 (en) 2005-09-01
DE60118798T2 (en) 2007-04-12
JP4445703B2 (en) 2010-04-07
EP1373524B1 (en) 2006-04-12
CA2425852C (en) 2009-09-29
US20050079488A1 (en) 2005-04-14
CN1247785C (en) 2006-03-29
EP1373524A2 (en) 2004-01-02
CN1469930A (en) 2004-01-21
ATE323166T1 (en) 2006-04-15
ZA200302667B (en) 2004-07-05
US7846687B2 (en) 2010-12-07
CA2425852A1 (en) 2002-04-18
WO2002031137A2 (en) 2002-04-18
WO2002031137A3 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
AU2002211710A1 (en) Cytomegalovirus intron a fragments
AU2001292183A1 (en) Jet, an artificial promoter for gene expression
AU4032300A (en) Method for generating transcriptionally active dna fragments
AU2001265187A1 (en) Chimeric viral vectors for gene therapy
AU6724194A (en) Nucleotide sequences for the control of the expression of dna sequences in a cellular host
AU2002236096A1 (en) Salmonella promoter for heterologous gene expression
AU8005598A (en) New uses for compounds which reduce (c-jun) gene expression
AU2002213937A1 (en) Method for modifying the genome of corynebacteria
AU2002212505A1 (en) Dna expression vectors
AU3425700A (en) Non-ribosomal peptide synthetases, method for producing same and the use thereof
AU2002306968A1 (en) Ogri gene disruptions, compositions and methods relating thereto
AUPQ262599A0 (en) Gene expression
AU2002347813A1 (en) Chimeric viral vectors for gene therapy
AU2735897A (en) Ribosomes as vectors for rna
AU2626699A (en) Self-replicating vector for dna immunization against hiv
AU3133799A (en) Seed-coat promoters, genes and gene products
AU2003259185A1 (en) Process for regulating gene expression
AU2001266740A1 (en) Promoters for regulated gene expression
AU2001296365A1 (en) Methods for cloning, sequencing and expressing genes from complex microbial populations
AU7567101A (en) Gene expression system
AU7116700A (en) Thermus promoters for gene expression
AU5561599A (en) Dna promoter sequence for gene expression
NZ533165A (en) Isolation tool for viable c-kit expressing cells
AU2002227069A1 (en) Methods for expressing endogenous genes by restriction enzyme mediated integration
AU2003267971A1 (en) Improved alphavirus vectors having attenuated virion structural proteins